miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6.
Chao LeiFeng DuLina SunTing LiTingyu LiYali MinAiying NieXin WangLei GengYuanyuan LuXiao-Di ZhaoYongquan ShiDaiming FanPublished in: Cell death & disease (2017)
Metastasis is a major clinical obstacle responsible for the high mortality and poor prognosis of gastric cancer (GC). MicroRNAs (miRNAs) are critical mediators of metastasis that act by modulating their target genes. In this study, we found that miR-143 and miR-145 act via a common target gene, MYO6, to regulate the epithelial-mesenchymal transition (EMT) and inhibit metastasis. We determined that miR-143 and miR-145 were downregulated in GC, and the ectopic expression of miR-143 and/or miR-145 inhibited GC cell migration and metastasis. Furthermore, MYO6 was identified as a direct common target of miR-143 and miR-145 and was elevated in GC. Silencing of MYO6 resulted in a metastasis-suppressive activity similar to that of miR-143 and miR-145, while restoring MYO6 attenuated the anti-metastatic or anti-EMT effects caused by miR-143 and miR-145. Clinically, an inverse correlation was observed between miR-143/145 levels and MYO6 levels in GC tissues, and either miR-143/145 downregulation or MYO6 upregulation was associated with more malignant phenotypes in patients with GC. In conclusion, miR-143 and miR-145 suppress GC cell migration and metastasis by inhibiting MYO6 expression and the EMT, which provides a novel mechanism and promising therapeutic target for the treatment of GC metastasis.
Keyphrases
- long non coding rna
- cell proliferation
- poor prognosis
- long noncoding rna
- epithelial mesenchymal transition
- cell migration
- signaling pathway
- squamous cell carcinoma
- small cell lung cancer
- type diabetes
- coronary artery disease
- dna methylation
- high resolution
- transcription factor
- combination therapy
- simultaneous determination